Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O15269: Variant p.Cys133Trp

Serine palmitoyltransferase 1
Gene: SPTLC1
Feedback?
Variant information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Cysteine (C) to Tryptophan (W) at position 133 (C133W, p.Cys133Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In HSAN1A; inactive in the heterodimeric SPT complex; largely reduced canonical activity towards serine; contrary to wild-type, uses alanine as substrate leading to the formation of 1-deoxysphinganine (1-deoxySa); does not affect the interaction with SPTLC2. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 473 The length of the canonical sequence.
Location on the sequence: help DNPRVKAAALASLKKYGVGT C GPRGFYGTFDVHLDLEDRLA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         DNPRVKAAALASLKKYGVGTCGPRGFYGTFDVHLDLEDRLA

Mouse                         ANPRVKATAFSSLKKYGVGTCGPRGFYGTFDVHLDLEERLA

Rat                           ANPRVKAAAFASLKKYGVGTCGPRGFYGTFDVHLDLEERLA

Bovine                        DNPRLKAAALASLKKYGVGTCGPRGFYGTFDVHLDLEDRLA

Caenorhabditis elegans        GVKRIEDRAKQTIFKYGVGSCGPRGFYGTVDVHLDLEKELA

Slime mold                    NNPEINKISENAIRKYGVGSCGPRGFYGTIDVHLDLEKKTA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 473 Serine palmitoyltransferase 1
Topological domain 37 – 473 Cytoplasmic
Alternative sequence 143 – 143 D -> E. In isoform 2.
Mutagenesis 138 – 138 F -> A. Decreased catalytic activity with L-serine and palmitoyl-CoA as substrates.



Literature citations
Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I.
Dawkins J.L.; Hulme D.J.; Brahmbhatt S.B.; Auer-Grumbach M.; Nicholson G.A.;
Nat. Genet. 27:309-312(2001)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1); VARIANTS HSAN1A TRP-133; TYR-133 AND ASP-144; A disease-causing mutation in the active site of serine palmitoyltransferase causes catalytic promiscuity.
Gable K.; Gupta S.D.; Han G.; Niranjanakumari S.; Harmon J.M.; Dunn T.M.;
J. Biol. Chem. 285:22846-22852(2010)
Cited for: BIOPHYSICOCHEMICAL PROPERTIES; CHARACTERIZATION OF VARIANT HSAN1A TRP-133; A systematic comparison of all mutations in hereditary sensory neuropathy type I (HSAN I) reveals that the G387A mutation is not disease associated.
Hornemann T.; Penno A.; Richard S.; Nicholson G.; van Dijk F.S.; Rotthier A.; Timmerman V.; von Eckardstein A.;
Neurogenetics 10:135-143(2009)
Cited for: CHARACTERIZATION OF VARIANTS HSAN1A TYR-133; TRP-133 AND ASP-144; CHARACTERIZATION OF VARIANT ALA-387; LACK OF ASSOCIATION OF VARIANT ALA-387 WITH HSAN1A; INTERACTION WITH SPTLC2; Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I.
Rotthier A.; Penno A.; Rautenstrauss B.; Auer-Grumbach M.; Stettner G.M.; Asselbergh B.; Van Hoof K.; Sticht H.; Levy N.; Timmerman V.; Hornemann T.; Janssens K.;
Hum. Mutat. 32:E2211-E2225(2011)
Cited for: VARIANT HSAN1A PHE-331; CHARACTERIZATION OF VARIANTS HSAN1A TRP-133; PHE-331 AND VAL-352; SUBCELLULAR LOCATION; Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort.
Davidson G.L.; Murphy S.M.; Polke J.M.; Laura M.; Salih M.A.; Muntoni F.; Blake J.; Brandner S.; Davies N.; Horvath R.; Price S.; Donaghy M.; Roberts M.; Foulds N.; Ramdharry G.; Soler D.; Lunn M.P.; Manji H.; Davis M.B.; Houlden H.; Reilly M.M.;
J. Neurol. 259:1673-1685(2012)
Cited for: VARIANT HSAN1A TRP-133; VARIANT GLY-310;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.